Spyre Therapeutics (NASDAQ:SYRE) is one of the 17 biotechnology stocks with more than 50% upside.
As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish. The stock had received coverage from 7 analysts, all of whom assigned Buy ratings. It has a projected median 1-year price target of $57.86, offering an upside of more than 66%.
Copyright: mikkolem / 123RF Stock Photo
On January 22, Spyre Therapeutics (NASDAQ:SYRE) announced plans for 2026, where it will prioritize six POC readouts. The company mentioned that its SKYLINE ulcerative colitis trial has seen SPY001 enrollment complete ahead of schedule, accelerating Part A readouts to sometime in the second quarter. The SKYWAY basket trial on rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis remains on track for fourth-quarter readouts in 2026. Financially, $783 million in pro forma cash, cash equivalents, and marketable securities as of September 30, 2025, provides a runway through the second half of 2028. The company also appointed Kate Tansey Chevlen as Chief Commercial Officer, who is a seasoned biopharma commercial leader.
Spyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company developing advanced antibody therapeutics for patients with inflammatory bowel disease (IBD). The company focuses on next-gen cures for conditions such as ulcerative colitis and Crohn’s disease. Its current pipeline includes SPY001, SPY002, SPY003, and some combination therapies.
While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
